|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01027468 |
|
Date of registration:
|
07/12/2009 |
|
Primary sponsor: |
|
|
Public title:
|
Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
|
|
Scientific title:
|
Functional, Morphological And Safety Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration - 3 Years Of Follow-up |
|
Date of first enrolment:
|
August 2009 |
|
Target sample size:
|
160 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT01027468 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Contacts
|
|
Name:
|
Stefan Sacu, PD Dr. |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Department of Ophthalmology, Medical University of Vienna, Austria |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- any subtype of neovascular age-related macular degeneration
- age of 50 years or older
- initial treatment with intravitreal bevacizumab between August 2005 and June 2006
Exclusion Criteria:
- previous vitrectomy
- presence of cystoid macular edema without choroidal neovascularization
- Uncontrolled sytemic disease
Age minimum:
50 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Neovascular Age-related Macular Degeneration
|
|
Intervention(s)
|
|
Drug: intravitreal application of bevacizumab
|
|
Primary Outcome(s)
|
|
Vision
[Time Frame: 3 years after first intravitreal bevacizumab treatment]
|
|
vision
[Time Frame: 3 years after initial intravitreal bevacizumab treatment]
|
|
Secondary Outcome(s)
|
|
systemic complications after treatment, Central retinal thickness
[Time Frame: 3 years after initial bevacizumab treatment]
|
|
Secondary ID(s)
|
|
EK 548/2009
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|